Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.52 |
| ▸ | PRKCG | P05129 | 3/20 | 0.52 |
| ▸ | PRKCB | P05771 | 3/20 | 0.52 |
| ▸ | PRKCA | P17252 | 3/20 | 0.52 |
| ▸ | PRKCH | P24723 | 3/20 | 0.52 |
| ▸ | PRKCI | P41743 | 3/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.52 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | PRKACA | P17612 | 2/20 | 0.48 |
| ▸ | PRKACG | P22612 | 2/20 | 0.48 |
| ▸ | PRKACB | P22694 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7434256 | 0.84 | PRKD3 (0.61) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL7427827 | 0.78 | PRKD3 (0.65) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL30077194 | 0.77 | CYP3A4 (0.52) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL9363729 | 0.77 | PRKD3 (0.71) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL2907776 | 0.75 | PRKD3 (0.64) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL2903536 | 0.75 | ROCK2 (0.61) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL2908388 | 0.74 | PRKD3 (0.57) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL9542920 | 0.73 | PRKD3 (0.69) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL2907368 | 0.73 | ROCK2 (0.65) | ROCK2ROCK1CYP3A4PRKD3PRKCG | |
| SCHEMBL9541958 | 0.73 | PRKD3 (0.65) | ROCK2ROCK1CYP3A4PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479386-A1 | Use of isoquinoline-derivatives for treating and preventing pigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-0956865-B2 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-0956865-B1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI PHARMA CORP (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6906061-B2 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2005-06-14 | — | — | US | disclosed |
| EP-1479386-A1 | Use of isoquinoline-derivatives for treating and preventing pigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004062666-A2 | USE OF RHO-KINASE INHIBITORRS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | UNIVERSITY COLLEGE LONDON (GB) | 2004-07-29 | — | — | WO | disclosed |
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | UEHATA MASAYOSHI (JP) | 2003-07-17 | — | — | US | disclosed |
| US-6451825-B1 | FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6218410-B1 | ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5747507-A | MYOCARDIAL DISEASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0654266-A1 | CARDIAC PROTECTIVE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | ROCK2 4/4885ROCK1 1/4885CYP3A4 3462/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CYP3A4 4667/4885 |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | ROCK2 4/4885ROCK1 1/4885CYP3A4 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.